GSE97204
Effect of selective glucocorticoid receptor modulation (SGRM) on gene expression in human prostate cancer cell lines
Human prostate cancer cell lines treated with androgen receptor (AR) agonists/antagonists and concurrent glucocorticoid receptor (GR) agonist/antagonists Overall design: Human prostate cancer cell lines in charcoal-stripped FCS-containing media were treated for 3 days with AR agonists (R1881 1nM) +/-antagonist (enzalutamide 10uM) and then pulsed with 2 or 6 hour treatment with GR agonist (Dex 100nM)  +/- antagonist (SGRM, 335 1uM and 297 1uM) after which RNA was collected and sequenced